GlassScriptPhysician profile
Katherine Strickland
NPI 1639360589
$10,410.67
in general payments reported to CMS, 2019-2025
20 companies · $865 in 2025
The $865 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $844 · 2022: $856 · 2023: $6,308 · 2024: $1,538 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,500 · Food and Beverage: $3,253 · Travel and Lodging: $933 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,500.00 |
| Food and Beverage | $3,252.67 |
| Travel and Lodging | $933.46 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $6,698.36 | 2021-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $878.96 | 2021-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $465.87 | 2021-2023 | Farxiga |
| Genzyme Corporation | $319.75 | 2022-2024 | |
| Amgen INC. | $299.32 | 2021-2024 | Parsabiv, Epogen |
| Ardelyx, INC. | $235.50 | 2024-2025 | Xphozah 30 Mg |
| Travere Therapeutics, INC. | $232.63 | 2023-2025 | Filspari |
| Akebia Therapeutics INC | $230.65 | 2021-2024 | Auryxia, Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $186.71 | 2022-2023 | |
| Pharming Healthcare, INC. | $130.00 | 2024 | Ruconest |
| Boston Scientific Corporation | $125.37 | 2024 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $120.65 | 2023 | Oxlumo |
| Otsuka America Pharmaceutical, INC. | $110.00 | 2021 | |
| Neurocrine Biosciences, INC. | $103.97 | 2023 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $80.19 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $78.41 | 2023 | Uplizna |
| Nxstage Medical, INC. | $47.34 | 2021 | |
| Leadiant Biosciences, INC. | $29.28 | 2024 | Carnitor |
| Cormedix INC. | $19.42 | 2024 | Defencath |
| Astellas Pharma US INC | $18.29 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Strickland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.